

2018 Primary biliary cirrhosis Drug Development- Pipeline Analysis Report

<https://marketpublishers.com/r/24535D65213EN.html>

Date: May 2018

Pages: 0

Price: US\$ 999.00 (Single User License)

ID: 24535D65213EN

Abstracts

Primary biliary cirrhosis (PBC) is a long term chronic and autoimmune disease in which the bile ducts are inflamed and gradually destroyed. This results in built of bile in the liver, resulting in damage to the liver. The rare disease has limited treatment options with FDA approving obeticholic acid plus ursodeoxycholic acid as a single therapy.

Over 25 companies and universities are focusing on developing treatment options for Primary biliary cirrhosis.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Primary biliary cirrhosis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Primary biliary cirrhosis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Primary biliary cirrhosis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of Figures

1.2 List of Tables

2 PRIMARY BILIARY CIRRHOSIS (PBC) PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview

2.2 Primary biliary cirrhosis (PBC) Pipeline Snapshot

2.3 Primary biliary cirrhosis (PBC) Pipeline by Phase

2.4 Primary biliary cirrhosis (PBC) Pipeline by Company

2.5 Primary biliary cirrhosis (PBC) Pipeline by Mechanism of Action

3 PRIMARY BILIARY CIRRHOSIS (PBC)- COMPANY WISE PIPELINE ANALYSIS

Albireo AB

Arena Pharmaceuticals

CymaBay Therapeutics

Enanta Pharmaceuticals

FF Pharma

Genfit

Genkyotex

GlaxoSmithKline

Intercept Pharmaceuticals

KAN Research Institute

NGM Biopharmaceuticals

Novartis

Phenex Pharmaceuticals

Retrophin

Suzhou Zelgen Biopharmaceutical Co Ltd

Tiziana Life Sciences

Virobay Inc

Zydus Cadila

4 PRIMARY BILIARY CIRRHOSIS (PBC) R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details

Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN PRIMARY BILIARY CIRRHOSIS (PBC) PIPELINE

6 APPENDIX

6.1 About VPA Research

6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Primary biliary cirrhosis (PBC) Pipeline by Phase, H1- 2018

Figure 2: Primary biliary cirrhosis (PBC) Pipeline by Companies, H1- 2018

Figure 3: Company Wise Pipeline Drug Phases, H1- 2018

Figure 4: Primary biliary cirrhosis (PBC) Pipeline by Mechanism of Action, H1- 2018

Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

List Of Tables

LIST OF TABLES

- Table 1: Primary biliary cirrhosis (PBC) Pipeline by Phase, H1- 2018
- Table 2: Primary biliary cirrhosis (PBC) Pipeline by Companies, H1- 2018
- Table 3: Primary biliary cirrhosis (PBC) Pipeline by Mechanism of Action, H1- 2018
- Table 4: Albireo AB Primary biliary cirrhosis Pipeline, May 2018
- Table 5: Arena Pharmaceuticals Primary biliary cirrhosis Pipeline, May 2018
- Table 6: CymaBay Therapeutics Primary biliary cirrhosis Pipeline, May 2018
- Table 7: Enanta Pharmaceuticals Primary biliary cirrhosis Pipeline, May 2018
- Table 8: FF Pharma Primary biliary cirrhosis Pipeline, May 2018
- Table 9: Genfit Primary biliary cirrhosis Pipeline, May 2018
- Table 10: Genkyotex Primary biliary cirrhosis Pipeline, May 2018
- Table 11: GlaxoSmithKline Primary biliary cirrhosis Pipeline, May 2018
- Table 12: Intercept Pharmaceuticals Primary biliary cirrhosis Pipeline, May 2018
- Table 13: KAN Research Institute Primary biliary cirrhosis Pipeline, May 2018
- Table 14: NGM Biopharmaceuticals Primary biliary cirrhosis Pipeline, May 2018
- Table 15: Novartis Primary biliary cirrhosis Pipeline, May 2018
- Table 16: Phenex Pharmaceuticals Primary biliary cirrhosis Pipeline, May 2018
- Table 17: Retrophin Primary biliary cirrhosis Pipeline, May 2018
- Table 18: Suzhou Zelgen Biopharmaceutical Co Ltd Primary biliary cirrhosis Pipeline, May 2018
- Table 19: Tiziana Life Sciences Primary biliary cirrhosis Pipeline, May 2018
- Table 20: Virobay Inc Primary biliary cirrhosis Pipeline, May 2018
- Table 21: Zydus Cadila Primary biliary cirrhosis Pipeline, May 2018

I would like to order

Product name: 2018 Primary biliary cirrhosis Drug Development- Pipeline Analysis Report

Product link: <https://marketpublishers.com/r/24535D65213EN.html>

Price: US\$ 999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/24535D65213EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970